4-(1-苯基)甲胺吡啶 | 58088-57-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 4-(1-苯基)甲胺吡啶
• 中文别名: 苯基吡啶-4-甲胺
• 英文名称: C-phenyl-C-pyridin-4-yl-methylamine
• 英文别名: (RS)-C-phenyl-C-pyridin-4-yl-methylamine；(RS)-α-(4-pyridyl)-benzyl amine；4-pyridyl-α-benzyl amine；Phenyl(pyridin-4-yl)methanamine
• CAS: 58088-57-6
• 化学式: C₁₂H₁₂N₂
• mdl: MFCD06589768
• 分子量: 184.241
• InChiKey: DNIOUOCUBMTIDC-UHFFFAOYSA-N

物化性质

• 熔点：
  104℃
• 沸点：
  335℃
• 密度：
  1.106
• 闪点：
  177℃

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.083
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2933399090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H317,H319

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: C-Phenyl-c-pyridin-4-yl-methylamine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: C-Phenyl-c-pyridin-4-yl-methylamine
CAS number: 58088-57-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H12N2
Molecular weight: 184.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(1-苯基)甲胺吡啶 生成 4-Amino-1-(pyrid-4-yl)-1,2,3,4-tetrahydroisoquinolin-3-one
  参考文献：
  名称：

  Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds

  摘要：

  公开了抑制β-淀粉样肽释放和/或其合成的化合物，因此可用于治疗阿尔茨海默病。还公开了包含抑制β-淀粉样肽释放和/或其合成的化合物的药物组合物，以及使用这些药物组合物预防性和治疗性地治疗阿尔茨海默病的方法。

  公开号：

  US06506782B1
• 作为产物：
  描述：

  苯基溴化镁 在 sodium borohydrid 、 ammonium chloride 作用下， 以 甲醇 为溶剂， 生成 4-(1-苯基)甲胺吡啶
  参考文献：
  名称：

  Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds

  摘要：

  公开了抑制β-淀粉样肽释放和/或其合成的化合物，因此可用于治疗阿尔茨海默病。还公开了包含抑制β-淀粉样肽释放和/或其合成的化合物的药物组合物，以及使用这些药物组合物预防性和治疗性地治疗阿尔茨海默病的方法。

  公开号：

  US06506782B1

文献信息

• Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
  申请人：——

  公开号：US20020045747A1

  公开（公告）日：2002-04-18

  Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

  公开了抑制β-淀粉样肽释放和/或其合成的化合物，因此可用于治疗阿尔茨海默病。还公开了包含抑制β-淀粉样肽释放和/或其合成的化合物的药物组合物，以及使用这些药物组合物预防性和治疗性治疗阿尔茨海默病的方法。
• Synthesis and gastric antisecretory activity of N-cyano-N'-(phenyl-pyridinylmethyl)guanidine derivatives.
  作者：KATSUTOSHI SHIMADA、HIDEAKI FUJISAKI、KIYOSHI OKETANI、MANABU MURAKAMI、TADAO SHOJI、TSUNEO WAKABAYASHI、KOICHIRO UEDA、KIICHI EMA、KAZUNORI HASHIMOTO、SATORU TANAKA

  DOI：10.1248/cpb.32.4893

  日期：——

  N-Alkyl-N'-cyano-N"-(substituted phenyl-pyridinylmethyl) guanidine derivatives were synthesized and tested for inhibitory activity against gastric secretion in rats. Several of the compounds synthesized showed an inhibiting activity as potent as that of cimetidine against basal gastric secretion but showed less potent activity than cimetidine against histamine-stimulated gastric secretion. Some structure-activity relationships are discussed.

  N-烷基-N'-氰基-N"-(取代苯基吡啶甲基)胍衍生物被合成并测试了对大鼠胃分泌的抑制活性。合成的化合物中，有几个展现了对基础胃分泌的抑制活性，与西咪替丁相当，但在对抗组胺刺激的胃分泌方面，活性不如西咪替丁。还讨论了一些结构-活性关系。
• Synthesis of primary amines via nucleophilic addition of organometallic reagents to aldimines on solid support
  作者：Alan R. Katritzky、Linghong Xie、Guifen Zhang、Michael Griffith、Karen Watson、John S. Kiely

  DOI：10.1016/s0040-4039(97)01639-0

  日期：1997.10

  of amine-functionalized Rink polystyrene resin with aldehydes, react with Grignard reagents, lithium reagents or LiBH4 to afford a wide variety of primary amines in good to excellent yields upon trifluoroacetic acid cleavage. In this amine synthesis, Rink resin functions both as a solid support and as a NH protecting group.

  源自胺官能化的Rink聚苯乙烯树脂与醛的缩合反应而得到的树脂固定的醛亚胺5与格氏试剂，锂试剂或LiBH 4反应，可以生成多种伯胺，在裂解三氟乙酸后，其收率高至优异。在这种胺合成中，Rink树脂既充当固体载体又充当NH保护基。
• Indole derivatives as inhibitors or factor Xa
  申请人：Aventis Pharma Deutschland GmbH

  公开号：US06337344B1

  公开（公告）日：2002-01-08

  The present invention relates to the inhibition of blood clotting proteins, and more particularly, to indole derivatives of formula (I), in which R1a, R1b, R1c R1d, R2, R3, R4 and A are defined as indicated in the claims. The compounds of formula (I) are inhibitors of the blood clotting enzyme factor Xa. The invention also relates to processes for the preparation of the compounds of formula (I), to methods of inhibiting factor Xa activity and of inhibiting blood clotting, to use of the compounds of formula (I) in the treatment and prophylaxis of diseases which can be cured or prevented by the inhibition of factor Xa activity such as thromboembolic diseases, and to the use of the compounds of formula (I) in the preparation of medicaments to be applied in such diseases. The invention further relates to compositions containing a compound of formula (I) in admixture or otherwise in association with an inert carrier, in particular pharmaceutical compositions containing a compound of formula (I) together with pharmaceutically acceptable carrier substances and/or auxiliary substances.

  本发明涉及抑制血液凝块蛋白，更具体地说是与式(I)中的吲哚衍生物有关，其中R1a、R1b、R1c、R1d、R2、R3、R4和A的定义如索赔中所示。式(I)化合物是血液凝块酶因子Xa的抑制剂。本发明还涉及制备式(I)化合物的方法，抑制因子Xa活性和血液凝块形成的方法，以及利用式(I)化合物在治疗和预防可通过抑制因子Xa活性治愈或预防的疾病中的用途，如血栓栓塞性疾病，并且利用式(I)化合物制备用于治疗此类疾病的药物。本发明还涉及含有式(I)化合物的组合物，与惰性载体混合或以其他方式与之结合，特别是含有式(I)化合物的药物组合物，连同药用载体物质和/或辅助物质。
• [EN] BROAD-SPECTRUM INHIBITORS OF FILOVIRUSES<br/>[FR] INHIBITEURS À LARGE SPECTRE DE FILOVIRUS
  申请人：MICROBIOTIX INC

  公开号：WO2018106667A1

  公开（公告）日：2018-06-14

  The present invention is related to the development of therapeutics and prophylactics for the treatment and/or prevention of filovirus infection in humans and other mammals. A new class of small molecules is disclosed that inhibits the interaction of naturally processed (i.e., proteolytically cleaved) filovirus glycoprotein (GPCL) with its host receptor Niemann-Pick C 1 (NPCl) protein and thus block infection of host cells by filoviruses. Also disclosed are methods of using the small molecule inhibitors in the treatment/prevention of filovirus infection.

  本发明涉及开发用于治疗和/或预防人类和其他哺乳动物的Filovirus感染的治疗和预防剂。揭示了一类新的小分子，它抑制了自然加工（即蛋白酶水解）的Filovirus糖蛋白（GPCL）与其宿主受体Niemann-Pick C1（NPC1）蛋白的相互作用，从而阻止Filovirus感染宿主细胞。还揭示了在治疗/预防Filovirus感染中使用小分子抑制剂的方法。